Benzinga EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment
GT Biopharma submitted an IND application for GTB-5550 TriKE for solid tumors. Phase 1 trial planned for 2026. read more
GT Biopharma submitted an IND application for GTB-5550 TriKE for solid tumors. Phase 1 trial planned for 2026. read more